Abbott and Neurocrine Biosciences have entered into a collaboration to develop and commercialize elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that has recently completed a Phase ...

The expanding use of GnRH antagonist protocols has enabled the use of a GnRH agonist as the trigger for final oocyte maturation. A GnRH agonist trigger clearly cannot be employed in a GnRH agonist ...

Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of therapy.